Tools to silence lncRNAs are currently available (RNA interference, antisense oligonucleotides and genome editing [CRISPR/Cas9 system]), but none have been clinically used for PVT1 (Arun et al, 2018) and warrant further investigation for ovarian cancers. Here, PVT1 is linked to ovarian cancer.